Mr. David Pidduck reports

MEDIPHARM LABS COMPLETES FIRST SHIPMENT TO FRANCE

Medipharm Labs Corp. has completed the company's first shipment to France.

This milestone follows a production agreement with an international medicinal cannabis organization. This strategic collaboration strengthens Medipharm's position as a trusted supplier of pharmaceutical-grade cannabis products and demonstrates the company's ability to meet stringent European regulatory standards. The French medicinal cannabis market is projected to experience significant growth over the coming years. Conservative estimates place the market at $187.6-million (U.S.) by 2025, rising to $213.3-million (U.S.) by 2030 under current regulatory conditions.

"Medipharm's completion of our first production order and subsequent shipment to France marks our entry into one of Europe's most promising emerging medical cannabis markets," said David Pidduck, chief executive officer of Medipharm Labs. "This achievement underscores our ability to establish new pathways to market and deliver pharmaceutical-grade products that meet stringent European standards."

Medipharm Labs continues to expand its global footprint through strategic distribution and pharmaceutical partnerships, leveraging industry-leading licenses from multiple regulatory authorities to access new markets and deliver innovative cannabinoid-based solutions worldwide. As of Q3 2025, international medical cannabis represented 56 per cent of Medipharm's total revenue. The 83-per-cent year-over-year growth in revenue for international medical cannabis was achieved through product portfolio expansion across multiple geographies.

Medipharm Labs has established distribution and supply partnerships across the globe, and now ships products to 10 countries, underscoring the company's commitment to advancing global health through trusted, compliant and high-quality cannabinoid offerings.

About Medipharm Labs Corp.

Founded in 2015, Medipharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a good manufacturing practices certified facility with ISO standard-built clean rooms. Medipharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. Medipharm Labs develops, formulates, processes, packages, and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets.

In 2021, Medipharm Labs received a pharmaceutical drug establishment licence from Health Canada, becoming the only company in North America to hold a commercial-scale domestic good manufacturing practices licence for the extraction of multiple natural cannabinoids. This GMP licence was the first step in the company's current foreign drug manufacturing site registration with the United States Food and Drug Administration.

In 2023, Medipharm acquired Vivo Cannabis Inc. which expanded Medipharm's reach to medical patients in Canada via Canna Farms medical e-commerce platform, and in Australia and Germany through Beacon Medical Pty. and Beacon Medical GmbH. This acquisition also included Harvest Medical Clinics in Canada which provides medical cannabis patients with physician consultations for medical cannabis education and prescriptions.

The company carries out its operations in compliance with all applicable laws in the countries in which it operates.

We seek Safe Harbor.